These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 18800232

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M, Goetghebeur M, Merikle E, Pandya A, Chu P, Taylor DC.
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [Abstract] [Full Text] [Related]

  • 3. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D, Park HJ, Ko SK.
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jönsson B, IDEAL Trial Investigators.
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD, Rattinger GB, Kuznik A, Koren MJ.
    Clin Ther; 2008 Jun; 30 Pt 2():2204-16. PubMed ID: 19281915
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V, Lobos JM, Serrano A, Brosa M, Capel M, Alvarez Sanz C.
    J Med Econ; 2012 Jun; 15 Suppl 1():45-54. PubMed ID: 22954062
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA, Casciano R, Stern L, Rejas J.
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [Abstract] [Full Text] [Related]

  • 10. Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
    Mark DB, Knight JD, Cowper PA, Davidson-Ray L, Anstrom KJ.
    Am Heart J; 2008 Oct; 156(4):698-705. PubMed ID: 18926150
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.
    Parthan A, Leahy KJ, O'Sullivan AK, Iakoubova OA, Bare LA, Devlin JJ, Weinstein MC.
    Pharmacoeconomics; 2013 Jun; 31(6):519-31. PubMed ID: 23585310
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
    Wagner M, Lindgren P, Merikle E, Goetghebeur M, Jönsson B.
    Can J Cardiol; 2009 Nov; 25(11):e362-9. PubMed ID: 19898698
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL, Lyseng-Williamson KA.
    Pharmacoeconomics; 2007 Nov; 25(12):1031-53. PubMed ID: 18047388
    [Abstract] [Full Text] [Related]

  • 19. International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
    Richard Hobbs FD, Gensini G, John Mancini GB, Manolis AJ, Bauer B, Genest J, Feldman RD, Harvey P, Jenssen TG, da Silva PM, JEWEL Study Group.
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):472-80. PubMed ID: 19407658
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
    Lafuma A, Colin X, Solesse A.
    Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.